Hypersensitivity Pneumonitis: Perspectives in Diagnosis and Management

Clinical behaviour of patients exposed to organic dust and diagnosed with idiopathic pulmonary fibrosis

“…The lack of internationally accepted guidelines for CHP makes differential diagnosis even more difficult, leading to high interobserver variability and low rates of definite diagnoses . Three recently published papers proposed diagnostic criteria and/or composite score systems to determine the probability of CHP in different clinical scenarios . As treatment of CHP and IPF is different, there is a high medical need for further studies addressing diagnostic and therapeutic aspects of this IPF‐CHP differential diagnosis.…”

Pulmonary Veno-Occlusive Disease: Pathogenesis, Risk Factors, Clinical Features and Diagnostic Algorithm—State of the Art

“…The morphology of centrilobular ground glass opacities seen in PVOD/PCH in HRCT is similar to that seen in hypersensitivity pneumonitis (HP) [29,36]. However, HP has other typical radiological features not seen in PVOD/PCH such as mosaic lung attenuation, air trapping or lung fibrosis [37,38]. Moreover, in most cases HP may be excluded basing on the lack of characteristic elements such as: a history of exposure to organic dusts, restrictive pattern on body plethysmography, and lymphocytosis in BALF [37,38].…”

“…However, HP has other typical radiological features not seen in PVOD/PCH such as mosaic lung attenuation, air trapping or lung fibrosis [37,38]. Moreover, in most cases HP may be excluded basing on the lack of characteristic elements such as: a history of exposure to organic dusts, restrictive pattern on body plethysmography, and lymphocytosis in BALF [37,38]. The details of differential diagnosis between HP and PVOD/PCH are listed in Table 3.…”

Lessons from the interstitial lung disease-India registry: A proposed practical scheme of classification of diffuse parenchymal lung diseases in the Indian subcontinent

“…Incidentally, the so-called “sure” or “possible” abnormality pattern is already proposed for sarcoidosis (as typical and atypical)[7] and upcoming for HP. [8] The left out cases of DPLD consisting of the “unknown” or “difficult to classify” patients should be dealt with multidisciplinary discussion (MDD). This identification of the DPLD with such “sure” or “possible” connotation certainly finds scope of support from the serological tests for sarcoidosis (serum angiotensin-converting enzyme), HP (IgG precipitin tests), and CVD (rheumatoid factor, antinuclear antibody, and further profile of autoantibodies).…”